Friday, Cardium Therapeutics announced Excellagen's introduction into U.S. markets. Excellagen is a wound care product for dermal wounds, such as diabetic foot ulcers and other types of pressure ulcers.
Cardium is focused on the acquisition and development of new bio-medical products. Currently, the company's portfolio, centered on health sciences and regenerative medicine, includes Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform. The company is also developing Generx, a product intended for the treatment of patients with myocardial ischemia due to coronary artery disease.
Excellagen is a syringe-based topical wound care product and has recently been cleared by the FDA. Cardium's initial marketing efforts for Excellagen will be web-based, supported by exhibiting the product at trade shows and building a network of patient assistance programs. The company is also preparing to distribute Excellagen through South Korea.
Christopher J. Reinhard, chairman and CEO of Cardium Therapeutics, said, "We are pleased to announce the market introduction of Excellagen, which is an important milestone for the Company. Following initial market introduction, we look forward to advancing the commercialization of Excellagen in the U.S. and into international markets with strategic and distribution partners having access to podiatrists and other wound care specialists. We are also pleased to announce our logistics agreement with Smith Medical Partners, a subsidiary of H. D. Smith and one of the leading national specialty distributors with strong logistics and cold chain capabilities, to provide exceptional ordering and customer support, inventory control and shipping logistics."
For more information, visit www.cardiumthx.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html